Skip to content

Trial Summary

A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter, Study of OP-1250 in Adult Subjects with advanced and/or metastatic Hormone Receptor (HR)-positive, HER2-negative breast cancer



ACTRN/NCT /ethics:


Scientific title:

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Sponsor / Cooperative group:

Olema Pharmaceuticals, Inc.

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-08-13
Anticipated End Date2023-12-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Phone08 8359 2565
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting